Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study
PLOS One · 07.07.2026 · 21 (7) · e0352017
DOI: 10.1371/journal.pone.0352017 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, online erschienen am 07.07.2026. Verfasst von Arta Grosmane-Bataraga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rīga Stradiņš University, Department of Doctoral Studies, Riga, Latvia. Hauptthemen laut MEDLINE: Myasthenia Gravis, Glial Fibrillary Acidic Protein, Neurofilament Proteins. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rīgas Stradiņa Universitāte, Vetenskapsrådet, HORIZON EUROPE Reforming and enhancing the European Research and Innovation system.
Abstract (Originalsprache)
Aims
To evaluate plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) as candidate biomarkers in myasthenia gravis (MG).
Methods
Ninety MG patients and 40 healthy controls were recruited. Disease severity was assessed by the Myasthenia Gravis Foundation of America (MGFA) classification, Myasthenia Gravis Composite (MGC) score, and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale. Plasma NfL and GFAP were quantified using Single Molecule Array (Simoa) assays.
Results
NfL and GFAP plasma concentration did not differ between MG and controls ( p > 0.05). Neither biomarker correlated with MG-ADL or MGC, and no differences were observed across MGFA classes (p > 0.05). Biomarker levels were unrelated to myasthenic crisis history or treatment exposure.
Conclusion
Plasma NfL and GFAP, although informative in other neuroimmunological and neurodegenerative conditions, do not distinguish MG from healthy controls and show no association with disease severity. This study adds to the emerging literature on NfL in MG and represents one of the larger controlled analyses incorporating both NfL and GFAP biomarkers in this disease. The findings argue against adopting NfL or GFAP for MG monitoring and highlight the need for MG-specific biomarker strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rīga Stradiņš University, Department of Doctoral Studies, Riga, Latvia.
- Pauls Stradiņš Clinical University Hospital, Department of Neurology, Riga, Latvia.
- Rīga Stradiņš University, Faculty of Medicine, Riga, Latvia.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
ORCID-Profile: Vladimirs Krutovs, Viktorija Ķēniņa
Förderung
- Rīgas Stradiņa Universitāte
- Vetenskapsrådet
- HORIZON EUROPE Reforming and enhancing the European Research and Innovation system
- Alzheimer’s Drug Discovery Foundation
- Alzheimer’s Association
- European Partnership on Metrology
- Cure Alzheimer’s Fund
- Olav Thon Stiftelsen
Zitieren
APA
Grosmane-Bataraga, A., Saluvēra, E., Roddate, M., Krutovs, V., Blennow, K., Zetterberg, H., Zolovs, M., Kurjāne, N., & Ķēniņa, V. (2026). Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PLOS One, 21(7), e0352017. https://doi.org/10.1371/journal.pone.0352017
Vancouver
Grosmane-Bataraga A, Saluvēra E, Roddate M, Krutovs V, Blennow K, Zetterberg H, et al. Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study. PLOS One. 2026;21(7):e0352017. doi:10.1371/journal.pone.0352017
BibTeX
@article{GrosmaneBataraga2026,
author = {Grosmane-Bataraga, Arta and Saluvēra, Evita and Roddate, Marija and Krutovs, Vladimirs and Blennow, Kaj and Zetterberg, Henrik and Zolovs, Maksims and Kurjāne, Nataļja and Ķēniņa, Viktorija},
title = {Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352017},
doi = {10.1371/journal.pone.0352017}
}
EUVIMED